en-clofert 50
(Androxal), in development by Repros Therapeutics Inc, is a non-steroidal estrogen
receptor antagonist that promotes gonadotropin-dependent testosterone secretion by
the testes.Enclomiphene 50 constitutes the trans-stereoisomer of clomiphene
citrate, a drug that has been widely prescribed for several decades for the
treatment of female ovulatory dysfunction.
In clinical trials conducted to date,
enclomiphene 50
demonstrated significant efficacy in the physiological restoration of testosterone
levels in males with secondary hypogonadism. The compound also exhibited an
unanticipated favorable effect on fasting plasma glucose; this result has been
accompanied by rapidly accumulating evidence from other researchers for a
bidirectional relationship between low serum testosterone and obesity/metabolic
syndrome (syndrome X) in men.
artesunate 50
is a water-soluble hemisuccinate derivative of artemisinin. It is unpredictable in
neutral remedy as well as the injectable formulation must be prepared right away
prior to use in 5% (w/v) sodium bicarbonate option to produce the salt sodium
artesunate. After parenteral management, it is swiftly hydrolyzed to the energetic
metabolite dihydroartemisinin. The dental formulation is possibly hydrolyzed
completely prior to getting in the systemic blood circulation. |